Abstract
Japan Tobacco Inc is developing JTT-130, an orally active microsomal triglyceride transfer protein inhibitor, for the potential treatment of hyperlipidemia. By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe.
| Original language | English |
|---|---|
| Pages (from-to) | 495-499 |
| Journal | IDRUGS |
| Volume | 9 |
| Issue number | 7 |
| Publication status | Published - 2006 |